HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Mar
16
FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025
Mar
16
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
13
DATE OF BOARD MEETING
Mar
06
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
05
VOLUNTARY ANNOUNCEMENT - INDACATEROL ACETATE AND MOMETASONE FUROATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
04
VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
02
VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
02
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Mar
02
APPOINTMENT OF AN EXECUTIVE DIRECTOR
Feb
26
CONNECTED TRANSACTION - DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY
Feb
16
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Feb
16
VOLUNTARY ANNOUNCEMENT - ROPIVACAINE LONG-ACTING INJECTION (SYH9089 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Feb
02
VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS DRUG REGISTRATION APPROVAL
Jan
30
VOLUNTARY ANNOUNCEMENT - ENTERING INTO A STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE MEDICINES
Jan
29
VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jan
23
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Jan
15
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025
Jan
13
VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan
12
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS
Jan
02
VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2026 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer